Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Olivier Rascol And NotAngleterre

List of bibliographic references

Number of relevant bibliographic references: 69.
Ident.Authors (with country if any)Title
000148 Olivier Rascol [France] ; Santiago Perez-Lloret ; Joaquim J. Ferreira [Portugal]New treatments for levodopa-induced motor complications.
000390 Erwan Bezard [République populaire de Chine] ; Elsa Y. Pioli ; Qin Li ; Françoise Girard ; Vincent Mutel ; Charlotte Keywood ; Francois Tison ; Olivier Rascol ; Sonia M. PoliThe mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
000699 Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins ; Kathryn A. Chung ; Robert A. Hauser ; Janis M. Miyasaki ; Anthony P. Nicholas ; Werner Poewe [Autriche] ; Klaus Seppi ; Olivier Rascol ; Mark A. Stacy ; John G. Nutt ; Caroline M. Tanner ; Alison Urkowitz ; Jean A. Jaglin ; Song GeWhich dyskinesia scale best detects treatment response?
000714 Anthony E. Lang [Canada] ; Eldad Melamed ; Werner Poewe [Autriche] ; Olivier RascolTrial designs used to study neuroprotective therapy in Parkinson's disease.
000840 Olivier RascolPhysical exercise in Parkinson disease: moving toward more robust evidence?
000992 C. Warren Olanow [États-Unis] ; Karl Kieburtz ; Olivier Rascol ; Werner Poewe [Autriche] ; Anthony H. Schapira ; Murat Emre ; Helena Nissinen ; Mika Leinonen ; Fabrizio StocchiFactors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
000B23 Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000B88 Florian Krismer [Autriche] ; Klaus Seppi ; François Tison ; Cristina Sampaio ; Anja Zangerl ; Cecilia Peralta ; Farid Yekhlef ; Imad Ghorayeb ; Fabienne Ory-Magne ; Monique Galitzky ; Maria Bozi ; Tommaso Scaravilli ; Carlo Colosimo ; Felix Geser ; Olivier Rascol ; Werner Poewe [Autriche] ; Niall P. Quinn ; Gregor K. WenningThe Unified Multiple System Atrophy Rating Scale: intrarater reliability.
000E81 Wassilios G. Meissner [France] ; Alexandra Foubert-Samier ; Sandrine Dupouy ; Angélique Gerdelat-Mas ; Rachel Debs ; Fabienne Marquant ; Valérie Cochen De Cock ; Olivier Rascol ; François Tison ; Anne Pavy-Le TraonAssessment of quality of life with the multiple system atrophy health-related quality of life scale.
001206 Wassilios G. Meissner [France] ; Alexandra Foubert-Samier [France] ; Sandrine Dupouy [France] ; Angélique Gerdelat-Mas [France] ; Rachel Debs [France] ; Fabienne Marquant [France] ; Valérie Cochen De Cock [France] ; Olivier Rascol [France] ; François Tison [France] ; Anne Pavy-Le Traon [France]Assessment of Quality of Life with the Multiple System Atrophy Health-Related Quality of Life Scale
001350 Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
001351 Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
001491 Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
001562 Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche]Milestones in Parkinson's disease therapeutics
001688 Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
001888 Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Drug-Induced Parkinsonism: A Review of 17 Years' Experience in a Regional Pharmacovigilance Center in France
001A05 Joaquim J. Ferreira [Portugal] ; Dulce Neutel [Portugal] ; Tiago Mestre [Portugal] ; Miguel Coelho [Portugal] ; Mário M. Rosa [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Skin cancer and Parkinson's disease
001A19 Birgit Högl [Autriche] ; Isabelle Arnulf [France] ; Cynthia Comella [États-Unis] ; Joaquim Ferreira [Portugal] ; Alex Iranzo [Espagne] ; Barbara Tilley [États-Unis] ; Claudia Trenkwalder [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis]Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations
001B37 Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
001C84 Joseph H. Friedman [États-Unis] ; Guido Alves [Norvège] ; Peter Hagell [Suède] ; Johan Marinus [Pays-Bas] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni]Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease
001D33 Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas]Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
001E47 Laurence Nègre-Pagès [France] ; Hélène Grandjean [France] ; Maryse Lapeyre-Mestre [France] ; Jean Louis Montastruc [France] ; Annie Fourrier [France] ; Jean Pierre Lépine [France] ; Olivier Rascol [France]Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study
001E61 Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database
001F70 Laurence Negre-Pages [France] ; Hélène Grandjean [France] ; Maryse Lapeyre-Mestre [France] ; Jean Louis Montastruc [France] ; Annie Fourrier [France] ; Jean Pierre Lepine [France] ; Olivier Rascol [France]Anxious and Depressive Symptoms in Parkinson's Disease: The French Cross-Sectionnal DoPAMiP Study
001F72 Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance Database
002397 Fabienne Ory-Magne [France] ; Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Sabrina Debruxelles [France] ; Igor Sibon [France] ; Cyril Goizet [France] ; Pierre Labauge [France] ; Patrice Menegon [France] ; Emmanuelle Uro-Coste [France] ; Bernardino Ghetti [États-Unis] ; Marie Bernadetle Delisle [France] ; Ruben Vidal [États-Unis] ; Olivier Rascol [France]Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498‐499InsTC)
002486 Olivier Rascol [France] ; Ludwig Schelosky [Suisse]123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
002527 Fabienne Ory-Magne [France] ; Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Sabrina Debruxelles [France] ; Igor Sibon [France] ; Cyril Goizet [France] ; Pierre Labauge [France] ; Patrice Menegon [France] ; Emmanuelle Uro-Coste [France] ; Bernardino Ghetti [États-Unis] ; Marie Bernadetle Delisle [France] ; Ruben Vidal [États-Unis] ; Olivier Rascol [France]Clinical Phenotype and Neuroimaging Findings in a French Family with Hereditary Ferritinopathy (FTL498-499InsTC)
002532 Olivier Rascol [France] ; Ludwig Schelosky [Suisse]123I-Metaiodobenzylguanidine Scintigraphy in Parkinson's Disease and Related Disorders
002635 Hubert H. Fernandez [États-Unis] ; Dag Aarsland [Norvège] ; Gilles Fénelon [France] ; Joseph H. Friedman [États-Unis] ; Laura Marsh [États-Unis] ; Alexander I. Tröster [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Scales to assess psychosis in Parkinson's disease: Critique and recommendations
002690 Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Placebo influences on dyskinesia in Parkinson's disease
002944 Laurence Nègre-Pagès [France] ; Wafa Regragui [Maroc] ; Didier Bouhassira [France] ; Héléne Grandjean [France] ; Olivier Rascol [France]Chronic pain in Parkinson's disease: The cross‐sectional French DoPaMiP survey
002A00 Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Cristina Sampaio [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations
002A01 Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Christina Sampaio [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Anxiety rating scales in Parkinson's disease: Critique and recommendations
002A28 C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
002A80 Laurence Negre-Pages [France] ; Wafa Regragui [Maroc] ; Didier Bouhassira [France] ; Hélène Grandjean [France] ; Olivier Rascol [France]Chronic Pain in Parkinson's Disease : The Cross-Sectional French DoPaMiP Survey
002B44 Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
002B75 Joaquim Ferreira [Portugal] ; João Maia Silva [Portugal] ; Rita Freire [Portugal] ; João Pignatelli [Portugal] ; Leonor Correia Guedes [Portugal] ; Alexandra Feij [Portugal] ; Mário Miguel Rosa [Portugal] ; Miguel Coelho [Portugal] ; João Costa [Portugal] ; Ana Noronha [Portugal] ; Russell Hewett [Portugal] ; A. Marques Gomes [Portugal] ; J. L. Cirne De Castro [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Skin cancers and precancerous lesions in Parkinson's disease patients
002B90 Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
002E88 Fabienne Ory-Magne [France] ; Christine Brefel-Courbon [France] ; Marion Simonetta-Moreau [France] ; Nelly Fabre [France] ; Jean Albert Lotterie [France] ; Patrick Chaynes [France] ; Isabelle Berry [France] ; Yves Lazorthes [France] ; Olivier Rascol [France]Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
003097 Fabienne Ory-Magne [France] ; Christine Brefel-Courbon [France] ; Marion Simonetta-Moreau [France] ; Nelly Fabre [France] ; Jean Albert Lotterie [France] ; Patrick Chaynes [France] ; Isabelle Berry [France] ; Yves Lazorthes [France] ; Olivier Rascol [France]Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
003494 Olivier Rascol [France]Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: An important but still unmet need
003542 Anne Pavy-Le Traon [France] ; Richard L. Hughson [Canada] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Nelly Fabre [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Cerebral autoregulation is preserved in multiple system atrophy: A transcranial Doppler study
003663 Anne Pavy-Le Traon [France] ; Richard L. Hughson [Canada] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Nelly Fabre [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Cerebral autoregulation is preserved in multiple system atrophy : A transcranial doppler study
003689 Agnès Sommet [France] ; Cécile Azaïs-Vuillemin [France] ; Haleh Bagheri [France] ; Olivier Rascol [France] ; Jean Louis Montastruc [France]Trimetazidine: A new cause for drug‐induced parkinsonism?
003924 Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
003942 Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; François Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France]Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
003A72 Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; Francois Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France]Effect of levodopa on pain threshold in Parkinson's disease : A clinical and positron emission tomography study
003C40 Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance
003C51 Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Carl Counsell [Portugal] ; Nir Giladi [Israël] ; Robert G. Holloway [États-Unis] ; Charity G. Moore [États-Unis] ; Gregor K. Wenning [Autriche] ; Melvin D. Yahr [États-Unis] ; Lisa Seidl [États-Unis]Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
003D38 Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]Dopaminagonists and fibrotic valvular heart disease: Further considerations
003D59 Pierre Payoux [France] ; Kader Boulanouar [France] ; Christine Sarramon [France] ; Nelly Fabre [France] ; Sylvie Descombes [France] ; Monique Galitsky [France] ; Claire Thalamas [France] ; Christine Brefel-Courbon [France] ; Umberto Sabatini [Italie] ; Claude Manelfe [France] ; François Chollet [France] ; Laurent Schmitt [France] ; Olivier Rascol [France]Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study
003E06 Gilles Angibaud [France] ; Claude Gaultier [France] ; Olivier Rascol [France]Atypical parkinsonism and Annonaceae consumption in New Caledonia
004103 Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study
004135 Patrice Péran [France] ; Olivier Rascol [France] ; Jean-François Démonet [France] ; Pierre Celsis [France] ; Jean-Luc Nespoulous [France] ; Bruno Dubois [France] ; Dominique Cardebat [France]Deficit of verb generation in nondemented patients with Parkinson's disease
004154 Christine Brefel-Courbon [France] ; Karine Desboeuf [France] ; Claire Thalamas [France] ; Monique Galitzky [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Clinical and economic analysis of spa therapy in Parkinson's disease
004164 Frédéric Courbon [France] ; Christine Brefel-Courbon [France] ; Claire Thalamas [France] ; Marie Jeanne Alibelli [France] ; Isabelle Berry [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease
004219 Christine Brefel-Courbon [France] ; Karine Desboeuf [France] ; Claire Thalamas [France] ; Monique Galitzky [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Clinical and economic analysis of spa therapy in Parkinson's disease
004752 Jean-Louis Montastruc [France] ; Olivier Rascol [France]Modafinil and pramipexole‐associated somnolence
004759 Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
004780 Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
004C17 Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Treatment of Parkinson's disease should begin with a dopamine agonist
004E23 Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France]A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
004E51 Olivier Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach
005428 Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
005915 Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France]Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
005A42 Olivier Rascol [France] ; U. Sabatini ; N. Fabre [France] ; J. M. Senard [France] ; M. Simonetta-Moreau [France] ; J. L. Montrastruc [France] ; M. Clanet [France] ; A. Rascol [France]Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
005B25 J. L. Montastruc [France] ; N. Fabre [France] ; Olivier Rascol [France] ; J. M. Senard [France] ; O. Blin [France]N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan
005C63 Olivier Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. RascolNaltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024